MediciNova gets notice of allowance from Japan for pending patent for MN-166

The company states: “MediciNova announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166, or ibudilast, for the treatment of macular injury associated with progressive multiple sclerosis. Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis. The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis. The allowed claims cover oral administration including tablets, capsules, granules, microbead dosage forms, and liquid dosage forms. The allowed claims cover a wide range of doses of MN-166 , a range of different dosing frequencies, and a range of different treatment periods.”